21 research outputs found

    Active incident TB among contacts by age, gender and their index cases' characteristics, Tbilisi, Georgia, 2010–2011.

    No full text
    1<p>index cases>17 years of age.</p><p><b>Abbreviations</b>: AFB – Acid-fast bacilli; SS – sputum smear; MDR – Multidrug-resistant.</p><p>Active incident TB among contacts by age, gender and their index cases' characteristics, Tbilisi, Georgia, 2010–2011.</p

    Socio-demographic and clinical characteristics of index tuberculosis (TB) cases, Tbilisi, Georgia, 2010–2011.

    No full text
    1<p>index cases>17 years of age.</p><p><b>Abbreviations:</b> AFB–Acid-fast bacilli; SS–sputum smear; MDR–Multidrug-resistant</p><p>Socio-demographic and clinical characteristics of index tuberculosis (TB) cases, Tbilisi, Georgia, 2010–2011.</p

    Active Co-prevalent and incident TB among contacts by age, gender and their index cases' characteristics, Tbilisi, Georgia, 2010–2011.

    No full text
    1<p>index cases>17 years of age.</p><p><b>Abbreviations</b>: AFB – Acid-fast bacilli; SS – sputum smear; MDR – Multidrug-resistant.</p><p>Active Co-prevalent and incident TB among contacts by age, gender and their index cases' characteristics, Tbilisi, Georgia, 2010–2011.</p

    S1 File -

    No full text
    ObjectiveStudying treatment duration for rifampicin-resistant and multidrug-resistant tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We aim to present a hypothesis generating approach to identify factors associated with shorter duration of treatment.Study design and settingWe conducted an individual patient data meta-analysis among MDR/RR-TB patients restricted to only those with successful treatment outcomes. Using multivariable linear regression, we estimated associations and their 95% confidence intervals (CI) between the outcome of individual deviation in treatment duration (in months) from the mean duration of their treatment site and patient characteristics, drug resistance, and treatments used.ResultsOverall, 6702 patients with successful treatment outcomes from 84 treatment sites were included. We found that factors commonly associated with poor treatment outcomes were also associated with longer treatment durations, relative to the site mean duration. Use of bedaquiline was associated with a 0.51 (95% CI: 0.15, 0.87) month decrease in duration of treatment, which was consistent across subgroups, while MDR/RR-TB with fluoroquinolone resistance was associated with 0.78 (95% CI: 0.36, 1.21) months increase.ConclusionWe describe a method to assess associations between clinical factors and treatment duration in observational studies of MDR/RR-TB patients, that may help identify patients who can benefit from shorter treatment.</div
    corecore